Cardiac Ablation Clinical Trials

Clinical trials related to Cardiac Ablation Procedure

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Status: Recruiting
Location: See all (28) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 1\. History of a single AF ablation procedure for PAF or PsAF within 3 years prior to enrollment 2. Documented evidence of symptomatic AF, AT or AFL recurrence at least 90 days after subject's de novo ablation procedure, as demonstrated by:

‣ A physicians' note indicating at least 1 symptomatic AF, AT, or AFL episode occurring within 12 months prior to the enrollment; and

⁃ At least 1 electrocardiographically documented episode of AF, AT, or AFL within 12 months prior to enrollment 3. Adults who are ≥18 years of age on the day of enrollment 4. Willing and able to comply with all study requirements and provide informed consent

Locations
United States
Alabama
University of Alabama at Birmingham (UAB) Hospital
NOT_YET_RECRUITING
Birmingham
California
Scripps Green Hospital
NOT_YET_RECRUITING
La Jolla
Cedars Sinai Medical Center
NOT_YET_RECRUITING
Los Angeles
Florida
NCH Rooney Heart Institute
RECRUITING
Naples
AdventHealth Cardiovascular Research Institute
NOT_YET_RECRUITING
Orlando
Georgia
Piedmont Heart Institute
NOT_YET_RECRUITING
Atlanta
Memorial Health University Medical Center
NOT_YET_RECRUITING
Savannah
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Missouri
Kansas City Heart Rhythm Institute (Midwest Heart and Vascular Specialist)
NOT_YET_RECRUITING
Kansas City
New York
Northwell Health Lenox Hill Hospital
NOT_YET_RECRUITING
New Hyde Park
NYU Langone Medical Center
NOT_YET_RECRUITING
New York
Montefiore Medical Center
NOT_YET_RECRUITING
The Bronx
Ohio
Cleveland Clinic Foundation
NOT_YET_RECRUITING
Cleveland
OhioHealth Research and Innovation Institute (OHRI)
NOT_YET_RECRUITING
Columbus
Pennsylvania
Hospital of the University of Pennsylvania
NOT_YET_RECRUITING
Philadelphia
Allegheny General Hospital
NOT_YET_RECRUITING
Pittsburgh
Tennessee
Vanderbilt University Medical Center
NOT_YET_RECRUITING
Nashville
Texas
Texas Cardiac Arrhythmia Research Foundation
RECRUITING
Dallas
Texas Health Fort Worth
NOT_YET_RECRUITING
Fort Worth
Virginia
Inova Fairfax Hospital
NOT_YET_RECRUITING
Falls Church
Centra Medical Group Stroobants Cardiovascular Center
NOT_YET_RECRUITING
Lynchburg
Sentara Norfolk General Hospital
NOT_YET_RECRUITING
Newport News
Other Locations
Australia
Adelaide University
NOT_YET_RECRUITING
Adelaide
The Royal Melbourne Hospital
RECRUITING
Parkville
Westmead Hospital
NOT_YET_RECRUITING
Westmead
Belgium
Universitair Ziekenhuis Brussel
NOT_YET_RECRUITING
Brussels
France
Clinique Pasteur
NOT_YET_RECRUITING
Toulouse
Switzerland
Inselspital - Universitätsspital Bern
NOT_YET_RECRUITING
Bern
Contact Information
Primary
Ryan S Radtke, Bachelors of Science- Biology
ryan.s.radtke@medtronic.com
712-941-9372
Time Frame
Start Date: 2026-04-08
Estimated Completion Date: 2028-03-29
Participants
Target number of participants: 400
Treatments
Experimental: Single Arm: Redo AF Ablation with Sphere-9 Catheter
Participants undergo a redo atrial fibrillation ablation using the Sphere-9 Catheter and the Affera Ablation System per study protocol. All subjects receive the same intervention with no control or comparator arm.
Related Therapeutic Areas
Sponsors
Leads: Medtronic Cardiac Ablation Solutions

This content was sourced from clinicaltrials.gov